Hypertension — a significant risk factor for recurrent stroke in patients with atrial fibrillation
https://doi.org/10.18705/1607-419X-2016-22-1-32-40
Abstract
Objective. The purpose of research was to study the indicators of daily monitoring of blood pressure (ABPM) in post-stroke patients with atrial fibrillation (AF) and their relationship to mortality.
Design and methods. We included 350 stroke survivors with non-valvular AF. The patients were divided into 3 groups according to the stroke severity assessed by NIHSS (National Institutes of Health Stroke Scale). All patients underwent ABPM at baseline, at 3‑and 6‑month follow-up.
Results. By the time of stroke onset, 72% of patients have already had AF, in 28% patient AF was newly verified. Systolic (SBP) and diastolic blood pressure (DBP) was significantly (p < 0,05) higher in patients with paroxysmal AF (n = 109), they had significantly (p < 0,05) lower degree of blood pressure (BP) decrease at baseline, 3 and 6 months. At 6 months, the group of patients with paroxysmal AF included 96 people, 13 patients (3,7%) died: 4 (2,6%) in group I; 3 (2,5%) — in group II, and 6 (7,7%) in group III. In the subgroup of died patients, there was a significant correlation (r = 0,56, p < 0,05) between insufficient nocturnal BP decline and the incidence of paroxysmal AF.
Conclusions. Our findings suggest an independent contribution of the abnormal daily BP profile to the increased frequency of night AF episodes and its association with high mortality in post-stroke patients.
About the Authors
I. L. Davydkin
Samara State Medical University
MD, PhD, DSc, Professor, Vice-Chancellor on Research and Innovations, Head, Department of Internal Diseases with the Course of Outpatient Therapy and Transfusiology, Director, Scientific Institution of Hematology, Transfusiology and Intensive Care,
Leading Hematologist of Health Care Ministry of Samara Region
I. A. Zolotovskaya
Samara State Medical University;
Samara City Outpatient Clinic № 9
Russian Federation
Russian Federation
MD, PhD, Assistant, Department of Internal Diseases with the Course of Outpatient Therapy and Transfusiology;
Head, Outpatient Department for Adults,
89 Chapaevskaya street, Samara, 443099
References
1. Vinereanu D. Risk factors for atherosclerotic disease: present and future. Herz. 2006;31(Suppl 3):5–24.
2. Schober KE, Maerz I. Assessment of left atrial appendage flow velocity and its relation to spontaneous echocardiographic contrast in 89 cats with myocardial disease. J Vet Intern Med. 2006;20(1):120–130.
3. Solun B, Marcoviciu D, Dicker D. Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke? Eur J Intern Med. 2009;20(2):125–131. doi: 10.1016/j.ejim.2008.07.001. Epub 2008 Nov 8
4. Lakshminarayan K, Anderson DC, Herzog CA, Qureshi AI. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist. 2008;14(3):143–150.
5. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719–2747. doi: 10.1093/eurheartj/ehs253
6. Chen LY, Shen WK. Epidemiology of atrial fibrillation: a current perspective. Heart Rhythm. 2007;4 (3 Suppl):1–6.
7. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49(5):565–571.
8. Wolk R, Somers VK. Obesity-related cardiovascular disease: implications of obstructive sleep apnea. Diabetes Obes Metab. 2006;8(3):250–860.
9. Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006;97 (4):532–537.
10. Levy S, Sbragia P. Remodelling in atrial fibrillation. Arch Mal Coeur Vaiss. 2005;98(4):308–312.
11. Chiang CE, Naditch-Brûlé L, Murin J, Goethals M, Inoue H, O’Neill J et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5(4):632–639.
12. Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J. 2012;33(15):1870–1877.
13. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res. 2011;
14. 89(4):744–753.
15. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96(4):1180–4.
16. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol. 2011;57(7):831–8.
Review
For citations:
Davydkin I.L., Zolotovskaya I.A. Hypertension — a significant risk factor for recurrent stroke in patients with atrial fibrillation. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2016;22(1):32-40. https://doi.org/10.18705/1607-419X-2016-22-1-32-40
Views:
1453
Email this article 